The toxicity of avagacestat, a sulfonamide-based gamma (c)-secretase inhibitor that was in development as a treatment for Alzheimer's disease, was evaluated in a comprehensive nonclinical toxicology program that included 6-month and 1-year repeat-dose toxicity studies in rats and dogs, respectively. There was a spectrum of mechanism-based changes attributed to inhibition of Notch signaling that regulates the differentiation and proliferation of cells throughout development and in adult tissues. In both rats and dogs, ovarian follicular degeneration and atrophy and a low incidence of granulosa cell hyperplasia and benign granulosa-thecal cell tumors were observed. Gastrointestinal (GI) findings, including goblet cell metaplasia, dilatation of intestinal crypts/glands, mucosal epithelial necrosis and regeneration, and villous atrophy, were limited to dogs that had clinical evidence of GI toxicity. Other avagacestat-related findings attributed to interference with Notch signaling included decreases in peripheral lymphocytes (T and/or B cells) and lymphoid depletion in lymph nodes and the spleen in both species, as well as epiphyseal cartilage and trabecular bone changes in rats. Pharmacologically mediated decreases in brain and cerebrospinal fluid levels of b-amyloid (Ab) peptides Ab40 and Ab42 and decreased expression of white blood cell mRNA levels of the Notch-regulated gene hairy and enhancer of split-1 confirmed target engagement at all doses. Reductions in brain Ab peptide levels (22 to 34%) in dogs after 1 year at exposures up to the no-observed-effect level for GI toxicity of 1.1Â the human plasma exposure, and reversible GI changes at a 3.2Â multiple, indicated that a sustained pharmacodynamic effect was attained at exposures without dose-limiting toxicity.
spleen, kidney, skin, intestine, and lung (Puig and Combs, 2013) . Multiple APP cleavage sites are utilized by c secretase, resulting in the formation of multiple Ab species composed of 36-43 amino acids, of which Ab42 is considered highly amyloidogenic (Selkoe, 2001) . Because of its role in Ab peptide generation, c secretase was a key drug target for prevention and therapy of AD (Mawuenyega et al., 2010; Wolfe and Kopan, 2004) .
Avagacestat is an oral c-secretase inhibitor that was being developed as a treatment for AD (Gillman et al., 2010) . Oral administration caused dose-dependent reductions in brain Ab40 and Ab42 levels following a single dose in rats (40% to 85%), and dose-related reductions in brain Ab40 after 4 daily doses in rats (28%-80%) and after 6 months of daily dosing in dogs (20%-56%) (Albright et al., 2013) . Moreover, Ab40 and Ab42 levels in the cerebrospinal fluid (CSF) were similarly reduced and highly correlative of brain levels in these nonclinical studies, indicating that CSF Ab is a useful surrogate marker for brain Ab levels. Although the amount of Ab reduction needed for clinical benefit is unknown, nonclinical studies suggest that modest reductions in brain Ab levels may be adequate. In particular, an approximately 25% reduction in brain Ab levels by a c-secretase inhibitor reversed Ab-induced cognitive deficits in a transgenic mouse model (Comery et al., 2005) . In a 28-day, multiple ascending dose phase 1 clinical study, dose-dependent reductions in CSF Ab were achieved in healthy young and elderly subjects at avagacestat doses >50 mg, with maximal CSF Ab reductions of 60%-65% at the highest dose of 150 mg (Dockens et al., 2012) . However, although avagacestat was well tolerated at 50 mg (with high discontinuation rates at 125 mg) in a randomized, placebo-controlled phase 2 clinical trial (Coric et al., 2012) , it generated only small reductions in CSF Ab40 (10%-15%) and Ab42 (5%-9%) in prodromal AD patients and failed to improve clinical outcomes after at least 1 year of treatment (Coric et al., 2015) and was discontinued from development.
Gamma secretase is expressed in a wide variety of adult tissues (H ebert et al., 2004) and mediates the processing of transmembrane protein substrates other than APP, including Notch receptors (Mumm et al., 2000) . This provides significant challenges in developing clinically tolerable c-secretase inhibitors for the treatment of AD. The Notch family of receptors is involved in the regulation of cell differentiation and proliferation (Artavanis-Tsakonas et al., 1999; Kadesch, 2000) . Consistent with an important role for c secretase in Notch signaling, chronic administration of c-secretase inhibitors has the potential for adverse effects including decreased enterocyte differentiation and goblet cell metaplasia with potential compromise of the mucosal integrity of the gastrointestinal (GI) tract; altered T and B cell maturation with atrophy of the thymus and the marginal zone of the spleen; and epithelial cell hyperplasia in the skin, an effect that preceded squamous cell carcinoma (Li et al., 2007; Milano et al., 2004; Wong et al., 2004) . Expression of mRNA for hairy and enhancer of split (HES)-1, a transcriptional repressor and downstream effector of Notch signaling (Kobayashi and Kageyama, 2014) , is diminished in rats administered c-secretase inhibitors (Milano et al., 2004; Searfoss et al., 2003) , including avagacestat (Albright et al., 2013) . However, in nonclinical studies up to 1 month in rats and 6 months in dogs, avagacestat significantly reduced brain Ab levels at doses that did not cause the toxicities associated with Notch inhibition (Albright et al., 2013) , and this separation of Ab reduction from severe mechanism-based toxicity supported the development of avagacestat as a potential treatment for AD.
The toxicity of avagacestat in animals was characterized in a comprehensive nonclinical toxicology program to establish a safe starting dose for clinical trials and to identify potential adverse effects during clinical development. Toxicological effects related to disruption of Notch signaling were predominant at avagacestat doses/systemic exposures greater than those needed for significant reductions in brain Ab levels, with 22%-28% reductions in brain Ab in dogs at 0.3Â the multiple of human exposure. The objective of this article is to characterize the nonclinical target-organ toxicities of avagacestat with chronic administration.
MATERIALS AND METHODS
These studies were conducted in compliance with U.S. Food and Drug Administration Good Laboratory Practice regulations, and all animal experiments were approved by the Institutional Animal Care and Use Committee of Bristol-Myers Squibb Company and conducted in accordance with the Guide for the Care and Use of Laboratory Animals.
Test Article
Avagacestat (BMS-708163) is a sulfonamide-based c-secretase inhibitor and is chemically described as (R)-2-(4-chloro-N-(2-fluoro-4-(1, 2, 4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5, 5, 5-trifluoropentanamide (Gillman et al., 2010) .
Animals
The species used in the toxicology studies were Crl: CD Sprague Dawley (SD) rats (Charles River Laboratories, Inc., St-Constant, Quebec, Canada, and Kingston, New York) and Beagle dogs (Marshall Bioresources, North Rose, New York). All animals were housed in environmentally controlled rooms maintained on a 12-h light-dark cycle with targeted ranges for humidity (30%-70%) and temperature (64 F-79 F) , and water and certified feed were provided ad libitum.
Doses Administered
Avagacestat was administered orally by gavage (rats) or in gelatin capsules (dogs). The test-article carrier and vehicle was 100% polyethylene glycol-400. A 6-month oral toxicity study was conducted in rats (25 per sex per group) at doses of 2-30 mg/kg/day for 6 months. Plasma concentrations of avagacestat were substantially higher in female rats than in male rats due to rapid metabolism and clearance in males (Clarke et al., 2009) , thus males received higher doses than females.
In the 1-year oral toxicity study in dogs (6 per sex per group), avagacestat doses of 0.3-6 mg/kg/day were evaluated. Due to adverse clinical observations and associated moribundity related to GI toxicity in females at 6 mg/kg/day, the high dose for females was reduced to 4.5 mg/kg/day from days 32 to 59 when treatment was discontinued and the remaining females in that dose group were euthanatized.
Chronic Studies

Dose Selection
Rat. Avagacestat was clinically well tolerated in rats when administered orally for 1 month at doses up to 100 mg/kg/day. The primary avagacestat-related changes were considered to be related to inhibition of Notch signaling pathways and included decreases in peripheral lymphocyte counts and morphologic changes in lymphoid tissues (spleen, thymus), bones (growth plate), ovaries, and small intestine (duodenum) of females at 30 and 100 mg/kg/day. Additionally, the liver and adrenal glands were target organs at these doses in females. All findings were partially or fully reversible after a 1-month recovery period. The high dose of 100 mg/kg/day in males and the low dose of 3 mg/kg/day in females were no-observed-adverse-effect levels (NOAELs). Systemic exposures (area under the curve [AUC]) at these doses were 3370 and 3980 ngÁh/ml, respectively. There were no substantive differences in the incidence and severity of target tissue changes at 30 and 100 mg/kg/day in female rats, consistent with generally comparable exposures at these doses.
In a subsequent 3-month oral toxicity study, avagacestat was clinically well tolerated in rats when administered at doses up to 30 mg/kg/day. The primary changes included decreases in peripheral lymphocyte counts and morphologic changes in lymphoid tissue, bone, ovaries, and the small intestine of females at 8 and/or 30 mg/kg/day. In addition, there were avagacestatrelated decreases in serum estradiol (0.5Â controls) with increases in follicle-stimulating hormone (FSH; up to 6Â controls) and luteinizing hormone (LH; up to 3Â controls) at 8 and 30 mg/kg/day as well as increases in pituitary gland weight (up to 23%) with correlative microscopic findings of hypertrophy and hyperplasia of basophilic cells in the pars distalis. Additional pathologic findings in females at 8 and 30 mg/kg/day included a dose-related minimal to moderate glomerulonephropathy and associated proteinuria (urinary total protein output 4Â and 17Â above controls, respectively). The liver and adrenal glands were also target organs at these doses in females. All findings were partially or fully reversible after a 2-month recovery period. The high dose of 30 mg/kg/day in males and the low dose of 2 mg/kg/day in females were NOELs with associated systemic AUC exposures of 4260 and 2930 ngÁh/mL, respectively.
In males, the high dose for the 6-month toxicity study was selected based on the demonstration of maximal systemic exposure at 30 mg/kg/day. In females, a high dose of 8 mg/kg/day was selected based on the spectrum of target organ changes observed at this dose after 3 months. Lower doses of 8 and 15 mg/ kg/day in males and 2, 4, and 6 mg/kg/day in females were selected to evaluate any exposure-response relationships. These doses were associated with avagacestat plasma concentrations of 0.8Â-1.6Â and 1.9Â-12Â human therapeutic exposure in male and female rats, respectively (Table 1) .
Dog. In a 2-week oral exploratory toxicity study in male dogs, avagacestat was administered at doses of 0.5, 2, and 10 mg/kg/ day. Avagacestat was clinically tolerated at doses 2 mg/kg/ day, but not at 10 mg/kg/day with 3 of 5 dogs becoming moribund in the second week of the study due to GI toxicity including clinical signs of watery and/or tarry stools and histopathologic changes in the duodenum characterized by mild to severe goblet cell metaplasia. Other changes were limited to generally mild, multifocal mononuclear cell infiltration in the liver at 2 and 10 mg/kg/day. The NOAEL was considered to be 2 mg/kg/day (AUC 2548 ngÁh/ml).
Avagacestat was clinically well tolerated by dogs when administered orally at doses up to 3 mg/kg/day for 6 months. The primary drug-related changes were considered to be related to inhibition of Notch signaling pathways and included decreased peripheral B-cell lymphocytes and morphologic changes in ovaries, spleen, peripheral lymph nodes, and the small intestine (duodenum). Changes in biomarker activity consistent with Notch inhibition were observed at the high dose, whereas generally dose-related decreases in brain Ab40 were present at all dose levels. Following a 2-month postdose period, ovarian and circulating B-cell lymphocyte changes were showing evidence of reversibility; all other drug-related changes were completely reversible. The low dose of 0.3 mg/kg/day was considered a NOEL in males and a NOAEL in females and resulted in systemic exposures of 960 and 1100 ngÁh/ml in males and females, respectively, with associated reductions in brain Ab40 of 20%-26%.
Based on these data, doses of 0.3, 1, 3, and 6 mg/kg/day were selected for the 1-year study. A 3-month postdose recovery period was selected based on the nature of the anticipated findings in multiple tissues (including ovary and peripheral blood) that had incompletely recovered after a 2-month postdose period in the 6-month oral toxicity study. The high dose of 6 mg/kg/day was selected to provide further definition of the maximum tolerated dose with repeated administration. The doses used for the 1-year dog study were associated with avagacestat exposure multiples of 1Â-4.8Â the human therapeutic exposures (Table 1) .
Parameters Evaluated
Rats. In the 6-month oral toxicity study with a 3-month postdose recovery period, rats were observed twice daily for changes in condition and behavior; individual body weights and food consumption were determined pretest and at least weekly; physical examinations were performed pretest and during weeks 4, 13, 26, and 39; ophthalmologic examinations were performed pretest and during weeks 12 and 26; routine hematology and serum chemistry were performed during weeks 4, 13, 26, 27, and 39; coagulation assessments were performed prior to scheduled necropsies during weeks 27 and 39; urinalysis was performed on urine collected for approximately 18 h during weeks 2, 4, 13, 26, and 39; and blood lymphocyte phenotyping for total T lymphocytes (CD3þ), T-helper lymphocytes (CD3þ/ CD4þ), cytotoxic T lymphocytes (CD3þ/CD8aþ), B lymphocytes (CD45RAþ), natural killer (NK) lymphocytes (CD3-/CD161aþ), and B lymphocytes expressing high levels of IgM (CD45RAþ/ Due to GI toxicity, the dose for female dogs was reduced to 4.5 mg/kg/day on day 32 and treatment discontinued on day 59.
IgM hi ) was performed on weeks 13, 26, 27, and 39. To assess Notch inhibition, white blood cell (WBC) HES-1 mRNA expression was assessed from peripheral blood samples collected approximately 5 h after a daily dose during week 26 and at the end of week 39 using methods previously described in Albright et al. (2013) . All animals were necropsied at study termination, selected organ weights were collected, and all animals were subjected to a thorough gross and microscopic evaluation of tissues. Additional sections of spleen were collected at necropsy into optimal cutting temperature embedding medium and frozen, sectioned, immunostained for B-cell (CD45RA and IgM) and T-cell (ab T-cell receptor) markers, and analyzed for marginal zone thickness (evaluated by IgM and CD45RA immunostaining), distribution (density) of IgMþ marginal zone B-cells, and T-cell distribution by confocal microscopy. Plasma concentrations of avagacestat were determined from blood samples collected after dosing on day 1 and at 6 months.
Dog. In the 1-year oral toxicity study with a 3-month postdose recovery period, dogs were observed twice daily for changes in condition and behavior; individual body weights were determined pretest and weekly; food consumption (qualitative) was assessed daily; physical examinations (including ophthalmologic and neurologic evaluations) were performed pretest and during weeks 13, 26, 39, and 52; ECG evaluations were performed pretest and during weeks 12, 25, 38, and 51; routine hematology, serum chemistry, and coagulation assessments were performed twice pretest and during weeks 4, 13, 17 (amylase and lipase only), 26, 39, 52, and 65; urinalysis was performed on urine collected for approximately 16 h pretest and during weeks 26, 52; and 66; serum T4 was assessed during weeks 52 and 66; blood lymphocyte phenotyping for total T lymphocytes (CD3þ), T-helper lymphocytes (CD3þ/CD4þ), cytotoxic T lymphocytes (CD3þ/CD8aþ); and total B lymphocytes (CD3-/B cellsþ) was performed twice pretest and during weeks 4, 26, 52, and 65; WBC HES-1 mRNA expression was assessed from peripheral blood samples twice during pretest and approximately 4 to 6 h after a daily dose on day 2 and during weeks 4, 17, 26, and 52; and plasma Trefoil Factor Family 3 protein levels (a possible biomarker of intestinal injury) were assessed twice during pretest and 4 to 6 h after a daily dose on days 2 and 8 and during weeks 4, 13, 26, 52, and 65. Plasma concentrations of avagacestat were determined after dosing on day 1 and after a daily dose during weeks 13, 26, 39, and 52 to assess systemic exposure. On the day of necropsy, plasma, CSF, and brain samples were collected approximately 4-6 h after the final dose of avagacestat to assess brain Ab40 and Ab42 peptide and plasma and CSF Ab40 levels. All animals were necropsied at study termination, selected organ weights were collected, and all animals were subjected to a thorough gross and microscopic evaluation of tissues.
RESULTS
Safety Multiples of Avagacestat
The systemic exposures achieved in rats and dogs in chronic toxicology studies were equivalent to or substantially higher than mean human AUC exposure at a clinical dose of 50 mg. Table 1 provides the multiples of human exposure (ratio of animal AUC to human AUC at the clinical dose of 50 mg) achieved in these toxicology studies. Since avagacestat is highly bound to dog, rat, and human serum proteins (96% and 98% in dog and rat, respectively, vs 97% in humans), multiples of human exposure were calculated using total concentration of the drug.
Pharmacodynamic Effects
In the dog, there were dose-related decreases (0.34Â-0.78Â controls) in Ab40 and Ab42 levels in the brain at ! 0.3 mg/kg/day indicating inhibition of APP processing through 1 year of treatment (Table 2) . Additionally, there were dose-related reductions (0.40Â-0.73Â controls) in CSF Ab40 levels at ! 1 mg/kg/day in males and at 3 mg/kg/day in females. Plasma Ab40 levels demonstrated a biphasic response with increases (1.18Â-1.82Â controls) at 1 mg/kg/day and decreases (0.42Â-0.89Â controls) at ! 3 mg/kg/day. Although the mechanism for this biphasic effect on plasma Ab40 levels is not understood, it has been observed with other c-secretase inhibitors (Henley et al., 2009 ) and may reflect Ab that is produced peripherally rather than in the central nervous system (Lanz et al., 2006) . Similar dose-related brain and CSF Ab reductions by avagacestat occur in rats, as reported elsewhere (Albright et al., 2013) .
Changes in gene expression as a consequence of Notch inhibition were assessed by measuring HES-1 mRNA levels in peripheral blood WBC. In rats after 6 months of dosing, there were decreases in WBC HES-1 mRNA levels (0.39Â-0.60Â control) in females at ! 2 mg/kg/day and in males (0.44Â control) at 30 mg/ kg/day (Table 3) . After a 3-month postdose recovery period, the WBC HES-1 mRNA levels in males at 30 mg/kg/day returned to control levels but in females remained reduced (0.32Â-0.68Â control). In dogs, there were generally dose-dependent decreases in WBC HES-1 mRNA levels at ! 0.3 mg/kg/day in both males (0.14Â-0.75Â control; Table 4 ) and females (0.23Â-0.82Â of control; Table 5 ) that occurred by day 2 and were sustained throughout the dosing period. At the end of the 3-month postdose recovery period, mean WBC HES-1 mRNA expression recovered to control levels in both males and females.
Pharmacologically Mediated Target-Organ Effects
Ovarian Effects
Rat. There was dose-related minimal to marked ovarian atrophy at ! 2 mg/kg/day, and a low incidence of minimal to marked granulosa cell hyperplasia and benign granulosa-thecal cell tumors at ! 6 mg/kg/day (Table 6 and Figure 1 ). In addition, there was mild to marked increased or abnormal mucification of the vaginal epithelium at all doses and an increased incidence of animals in diestrus at ! 6 mg/kg/day indicating alteration or inhibition of estrous cyclicity. The ovarian changes in these studies correlated with generally dose-related decreases in absolute and relative (to body and/or brain weight) ovary weights (20%-74%) with associated decreases in absolute and relative (to body and to brain) uterine weights (15%-39%). Changes present after the 3-month recovery period included minimal ovarian granulosa cell hyperplasia at ! 4 mg/kg/day, an increased incidence of minimal to marked ovarian atrophy and slight to moderate increased/abnormal vaginal mucification at ! 6 mg/kg/day, and a benign ovarian granulosa-thecal cell tumor in 1 rat at 8 mg/kg/day. Dog. Microscopic changes in the ovaries were observed in 1 female at 0.3 mg/kg/day and all females at ! 1 mg/kg/day (Table 7) . The primary ovarian change was minimal to marked follicular degeneration characterized by degeneration and/or mineralization of ova and/or the absence of oocytes in secondary or tertiary follicles. Additional changes identified following 1 year of treatment included hypertrophy/hyperplasia of thecal cells (minimal to moderate) and granulosa cells (slight) at ! 1 mg/kg/day and a benign granulosa-thecal cell tumor in 1 dog at 3 mg/kg/day. The follicular degeneration correlated with generally dose-related decreases in absolute and relative (to body and/or brain weight) ovary weights (14%-55% compared with concurrent controls) at ! 0.3 mg/kg/day. The vagina, uterus, cervix, and mammary gland were unremarkable microscopically suggesting that these avagacestat-treated females continued to cycle. After a 3-month recovery period, residual ovarian changes were limited to generally minimal to mild follicular degeneration at 1 mg/kg/day. Given the normally prolonged estrous cycle in the dog of up to 10 months (Fowler et al., 1971; Jochle and Andersen, 1977) , the delayed or incomplete For controls and doses 1 mg/kg/day, n ¼ 4; for doses ! 3 mg/kg/day, n ¼ 3. ND, not determined. Females received 6 mg/kg/day through day 31; due to GI toxicity, the dose in females was reduced to 4.5 mg/kg/day between days 32 and 59 when treatment was discontinued and all remaining females were euthanatized.
a Fold change relative to controls (treated mean Ä control mean). SD, standard deviation.
Significantly different (*p .05; **p .01) from vehicle control based on the Dunnett multiple comparison t-test procedure. restoration of normal follicular activity at 3 months after cessation of avagacestat treatment was anticipated.
GI Toxicity
Rat. Although minimal goblet cell metaplasia has been observed in female rats receiving avagacestat at ! 30 mg/kg/day for 1 month (Albright et al., 2013) , goblet cell metaplasia was not observed in female rats receiving up to 8 mg/kg/day or in male rats at any dose.
Dog. At ! 3 mg/kg/day, several dogs were euthanatized after 16 to 191 days of treatment due to avagacestat-related GI toxicity (eg, intermittent red and/or black feces, pallor [skin and/or mucous membranes], inappetence, and loss of body weight). The onset of these signs was sporadic and ranged from approximately 2 weeks to 6 months after initiation of dosing. Clinical pathology changes in most of these dogs included increases in circulating neutrophil and monocyte counts, fibrinogen, and serum globulins that were consistent with an inflammatory Week 65 of the study is the end of the 3-month postdose recovery period.
Significantly different (least-squares adjusted means; *p .05; **p .01) from vehicle control based on the Dunnett multiple comparison t-test procedure. Week 65 of the study is the end of the 3-month postdose recovery period.
Significantly different (least-squares adjusted means; *p .05; **p .01) from vehicle control based on the Dunnett multiple comparison t-test procedure.
response; decreases in platelets that were attributed to increased consumption in the GI tract; and reductions in red blood cell parameters (red blood cell count, hematocrit, and hemoglobin concentration) and serum albumin that were attributed to enteric hemorrhage and loss of protein. In some early decedents, avagacestat-related macroscopic findings included pale, clear fluid in the abdomen (consistent with ascites); pancreatic edema; thickening of the stomach and duodenum; and dark and/or raised areas in the stomach and colon. Avagacestat-related microscopic findings in these early decedents included edema and ulceration of the glandular mucosa in the stomach; dilatation of intestinal glands (crypts), mucosal epithelial necrosis and regeneration, and goblet cell metaplasia ( Figure 2 ) and edema, subacute inflammation, and hemorrhage in multiple segments of the small and large intestines; villous atrophy in the duodenum and ileum; and lymphoid depletion in the gut-associated lymphoid tissues (GALTs) in the small intestine (Table 8) . These findings generally were most pronounced in the proximal duodenum with lesser involvement of more distal portions of the GI tract.
In dogs at ! 3 mg/kg/day with no clinical evidence of GI toxicity, there were no macroscopic findings in the GI tract. However, there were microscopic findings in the GI tract at 3 and 6 mg/kg/day including: (1) minimal goblet cell metaplasia in the duodenum; (2) minimal to moderate subacute inflammation at all levels of the small intestine and in the colon; (3) minimal to slight lacteal dilatation throughout the small intestine; (4) minimal to moderate regeneration of intestinal glands in the jejunum and throughout the large intestine; and (5) slight to moderate lymphoid depletion in the GALT in the ileum. After a 3-month postdose recovery period, there were no avagacestatrelated morphologic changes in the GI tract.
Mean and individual plasma levels of TTF3, an epithelial trefoil peptide found throughout the intestine that has been suggested to play a role in mucin polymerization and in repair and healing of the GI tract with upregulation at sites of mucosal injury (Suemori et al., 1991; Wong et al., 1999) , were highly variable. However, although increased plasma TTF3 levels (1.47Â-3.6Â pretest; data not shown) were identified in several avagacestattreated dogs with GI toxicity at ! 3 mg/kg/day, the magnitude of the increases generally did not correlate with the severity of the GI injury in these dogs.
Lymphoid Tissue Effects
Rat. Lymphoid depletion of the marginal zone and perarteriolar lymphoid sheaths (PALS) in the spleen (minimal to severe) and lymph node paracortices (minimal to moderate) were observed in females at ! 4 mg/kg/day (Table 6 ). Splenic immunophenotyping revealed dose-related decreases in marginal zone thickness and IgMþ B-cell density and decreased T-cell density in the PALS at ! 2 mg/kg/day in females. Morphologic changes in the spleen and lymph nodes correlated with decreases in total circulating lymphocyte counts principally due to dosedependent decreases in circulating T cells including both T-helper (CD4þ) and cytotoxic T (CD8þ) subtypes (Table 9) . In males at 15 and 30 mg/kg/day, decreases in circulating T cells (0.70Â-0.76Â control) were also noted, and morphologic changes in lymphoid tissues in males were limited to minimally decreased T-cell density in the PALS of the spleen at 30 mg/kg/ day (and only observable with splenic immunophenotyping). All avagacestat-related lymphoid changes in rats were partially or fully reversible after a 3-month postdose recovery period. Notably, these alterations in lymphoid tissue morphology and circulating lymphocyte counts were not associated with increased secondary or opportunistic infections.
Dog. Peripheral blood immunophenotyping assessments identified dose-related decreases (0.13Â-0.72Â control) in mean (least-squares adjusted) absolute B-cell counts at ! 1 mg/kg/day (Table 10 ) with decreases in total lymphocyte counts (0.50Â-0.77Â pretest) in individual animals from weeks 4 through 52 that were likely reflective of the decreases in B cells. The decreases in peripheral B cells at ! 3 mg/kg/day generally increased in magnitude with longer dosing and were more pronounced in females than in males. There were no avagacestatrelated effects on populations of T-helper or cytotoxic T lymphocytes (data not shown). The decreases in circulating B cells correlated with the microscopic finding of lymphoid depletion in the mandibular and mesenteric lymph nodes (minimal to moderate) and spleen (minimal to marked) at ! 3 mg/kg/day. Lymphoid depletion in lymph nodes was characterized by fewer germinal centers and altered germinal center development, whereas in the spleen the inner marginal zone (Figure 2 ) was most affected. After 3 months without treatment, there was complete recovery of all avagacestat-related microscopic changes in lymphoid tissues, while absolute counts of circulating B cells at ! 1 mg/kg/day partially recovered.
Avagacestat-related changes in the thymus were limited to minimal to marked lymphoid atrophy in early decedent dogs. As avagacestat-related changes were not present in the thymus of dogs in the absence of weight loss or in rats at higher systemic avagacestat exposures, these thymic changes in early decedent dogs were considered to be likely a consequence of stress. A dash (-) indicates the absence of test article-related finding in a group.
Bone Effects
Rat. In females, there was minimal to marked intramedullary trabecular hyperostosis at ! 2 mg/kg/day in the femur and at ! 4 mg/kg/day in the sternum and minimal to slight epiphyseal cartilage hypertrophy and/or hyperplasia in the femur at ! 6 mg/kg/day (Table 6 ). Trabecular hyperostosis consisted of increased number and/or thickness of trabeculae (mixed woven and lamellar bone) in the medullary cavity of the sternum and in the diaphysis of the femur. Cartilage hypertrophy/hyperplasia occurred in the epiphysis just under the articular surface cartilage and consisted of an increased number and/or size of chondrocytes. After a 3-month postdose recovery period, these findings persisted and were of a generally comparable severity and/or a slightly increased incidence compared with the end of dosing with increased amounts of mature lamellar bone compared with mixed woven and lamellar bone at the end of dosing that was consistent with an ongoing bone remodeling process (Figure 3 ).
Hematologic/Hematopoietic Effects
Rat. Increases (1.5Â-2.5Â control) in absolute eosinophil counts were observed in female rats at ! 4 mg/kg/day and were fully reversible. This finding was considered to be possibly pharmacologically mediated and related to inhibition of Notch signaling pathways as eosinophilic differentiation in umbilical cord blood cells was promoted by blockage of Notch signaling with a c-secretase inhibitor (Kang et al., 2005) .
Nonpharmacologic and Secondary Effects
Body Weight Effects Rat. In females, there were dose-dependent increases in body weight (8%-28%) at ! 2 mg/kg/day and in food consumption (up Females received 6 mg/kg/day through day 31; due to GI toxicity, the dose in females was reduced to 4.5 mg/kg/day between days 32 and 59 when treatment was discontinued and all remaining females were euthanatized.
to 27%) at ! 4 mg/kg/day. These body weight and food consumption increases were reversible with the 3-month recovery period. There were no avagacestat-related effects on body weight or food consumption in males at any dose.
Dog. There were no avagacestat-related effects on body weight or food consumption at doses up to 1 mg/kg/day. Mean body weights were decreased relative to controls by up to 8% in males at ! 3 mg/kg/day and up to 15% in females at 3 mg/kg/day, which correlated with dose-dependent decreases in mean body weight gain and reduced food consumption (qualitative) in these groups. Loss of body weight and thin body condition were observed in early decedent dogs at 3 or 6 mg/kg/day.
Pituitary and Adrenal Gland Effects
Rat. In the pituitary gland in females, there were avagacestatrelated absolute and/or relative (to body and/or to brain) weight increases (8%-48%) at ! 2 mg/kg/day that correlated microscopically with minimal to slight hyperplasia of basophilic cells (gonadotrophs) in the pars distalis (Table 11 ). In addition, there were minimally to moderately increased numbers of vacuolated/ hypertrophic basophilic cells at ! 6 mg/kg/day. Following a 3-month postdose period, there was partial recovery of these changes with persistent findings of increased pituitary gland weights (20%-59%) at ! 6 mg/kg/day, minimal to slight hyperplasia of basophil cells at ! 2 mg/kg/day, and a minimal increase in vacuolated/hypertrophic gonadotrophs in 1 rat at 8 mg/kg/day. Changes in the adrenal glands were observed at ! 2 mg/kg/day in females and consisted of increased absolute and relative (to brain) adrenal gland weights (18%-32%) with corresponding microscopic findings of minimal to mild cortical cell hypertrophy within the zona fasciculata (Table 11) . Although there were no adrenal gland weight changes after the recovery period, it was unclear if there was recovery of the adrenal cortical hypertrophy as this microscopic finding occurred at generally low and nondose-related incidences in all treated groups (data not shown).
Renal Effects
Rat. There were no avagacestat-related kidney findings in male rats. In females, there were increases in mean urinary total protein concentration (2.15Â-16.64Â control), urinary total protein output (4.14Â-14.51Â control), and total protein/creatinine ratio (3.93Â-13.11Â control) at doses ! 4 mg/kg/day and increases in urinary microalbumin concentration (3.07Â-45.88Â control), microalbumin output (2.33Â-42.98Â control), and microalbumin/creatinine ratio (2.39Â-47.91Â control) at doses ! 2 mg/kg/ day. Urinary protein excretion was monitored at multiple time points across the study (data not shown), and increases in urinary total protein parameters (1.64Â-2.13Â control) and microalbumin (2.19Â-3.91Â control) outputs were first observed after 2 weeks at the highest dose of 8 mg/kg/day. The increases in both urine protein and microalbumin were time-and generally dose-dependent with the greatest excretion at 6 months. These increased urine protein measurements in females were associated with minimal to moderate glomerulopathy at ! 4 mg/kg/day (Table 11) that was characterized by segmental clusters of eosinophilic granular material in the mesangium that at higher severities distended the mesangial space. In addition, there was dose-related minimal to marked chronic progressive nephropathy (CPN) at ! 2 mg/kg/day. Following a 3-month recovery period increases in urinary total protein parameters (1.54Â-18.72Â control) and microalbumin (2.02Â-29.51Â control) outputs persisted in females given ! 4 mg/ kg/day. Microscopically, there was minimal to mild glomerulopathy as well as increases in the incidence of mild to moderate CPN at ! 6 mg/kg/day relative to concurrent controls. The incidence and severity of these glomerular findings were reduced compared with the end of dosing, indicating partial recovery.
Liver Effects
Rat. Increases in mean absolute and relative (to body and to brain weight) liver weights (14%-57%) were observed in females at ! 2 mg/kg/day that were considered likely due to the induction of hepatic drug-metabolizing enzymes. Microscopically, there was minimal to moderate periportal vacuolation of hepatocytes at ! 6 mg/kg/day (confirmed in shorter-term studies as neutral lipids by oil red O staining). Increased hepatocellular Males received 6 mg/kg/day throughout the study. Females received 6 mg/kg/day through day 31; due to GI toxicity the dose was reduced to 4.5 mg/kg/day between days 32 and 59 when treatment was discontinued and all remaining females were euthanatized.
periportal lipid vacuolation likely did not contribute significantly to the increased liver weight. All liver changes in rats were fully reversible following postdose recovery periods of up to 3 months.
Dog. Minimal to moderate hypertrophy of sinusoidal lining cells (Kupffer cells) and mixed inflammatory cell infiltrates, and less commonly, minimal to slight hepatocellular necrosis (Figure 4 ) with correlative increases in serum alanine and aspartate aminotransferase activities (ALT: up to 12Â pretest; AST: up to 14Â pretest) were identified in some early decedent dogs at ! 3 mg/kg/day. Since these hepatic changes were only seen in dogs with pronounced GI toxicity, they likely were secondary to extensive intestinal mucosal injury with associated increased hepatic exposure to enteric bacteria and their products (eg, endotoxin) via the portal circulation rather than a direct effect of avagacestat.
Pancreas and Gallbladder Effects
Dog. Pancreatic swelling with edema (Figure 4) , inflammation, and acinar cell degeneration in the pancreas and necrosis of peripancreatic adipose tissue were identified in some early decedent dogs with severe GI toxicity and associated ascites due to enteric protein loss. Additionally, edema and inflammatory cell infiltrates were evident microscopically in the gallbladder.
Testes Effects
Dog. Minimal to moderate degeneration/necrosis of seminiferous tubular epithelium was observed in 3 early decedent dogs at 3 and 6 mg/kg/day necropsied between days 59 and 142.
DISCUSSION
The chronic repeat-dose toxicity of avagacestat was investigated in a comprehensive toxicity evaluation in animals. The primary findings were considered to be pharmacologically mediated (Table 12 ) due to inhibition of Notch signaling pathways that mediate cell-cell communications regulating the differentiation and proliferation of cells throughout development and in adult tissues (Artavanis-Tsakonas et al., 1999; Kadesch, 2000; Kopan and Ilagan, 2009 ). Specifically, these included decreases in circulating T and/or B lymphocytes and morphologic changes in lymphoid tissues, ovaries, bone (rats only), and the GI tract. These Notch-related effects demonstrated clear exposureresponse relationships in each species, with a NOEL for doselimiting GI effects in dogs of approximately 1.1Â human exposure at a dose of 50 mg. Plasma concentrations of avagacestat were generally similar between male and female dogs (Table 1) . However, exposures in male rats were notably lower than in The numerical values in the table represent the fold difference from the control mean value; treatment group mean/control group mean. a Males received 6 mg/kg/day throughout the study. Females received 6 mg/kg/ day through day 31; due to GI toxicity, the dose was reduced to 4.5 mg/kg/day between days 32 and 59 when treatment was discontinued and all remaining females were euthanatized. female rats due to rapid metabolism and clearance, and this sex difference in exposure likely explains the reduced toxicity in male rats. One of the challenges in developing tolerable c-secretase inhibitors for treating AD was that c secretase cleaves proteins in addition to APP, including the Notch family of transmembrane receptors. Therefore, c-secretase inhibitors are expected to inhibit Notch signaling pathways at some threshold of systemic exposure. In vitro cellular assays indicated that avagacestat inhibited Notch signaling and APP cleavage with IC 50 values of approximately 58 and 0.3 nM, respectively, resulting in a Notch/APP selectivity ratio of 193Â (Gillman et al., 2010) . Others using different cell-based and enzyme assays have reported considerably lower Notch/APP selectivity ratios (2.9Â-26Â) for avagacestat (Ch avez-Gutierrez et al., 2012; Crump et al., 2012; Martone et al., 2009; Mitani et al., 2012) , indicating variability in selectivity measurements between assays. Given this wide range in estimated Notch/APP selectivity ratios, the toxicities related to interference with Notch signaling pathways in these nonclinical studies at low multiples of projected therapeutic avagacestat plasma exposure (1.9Â-10.1Â in rats and 0.3Â-3.2Â in dogs based on lowest-observed-effect levels [LOELs]) were consistent with a modest therapeutic window for avagacestat (Albright et al., 2013) and supported diligent advancement into phase 2 clinical trials.
The reductions in peripheral WBC HES-1 mRNA levels observed in female rats (!3 mg/kg/day) and in dogs (!0.3 mg/kg/day) confirmed pharmacologically mediated inhibition of Notch signaling pathways in these studies. Because mRNA levels for each biomarker in each animal were normalized against the corresponding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA control, these decreases in HES-1 mRNA levels were not a reflection of avagacestat-related decreases in circulating lymphocytes. Reductions in WBC HES-1 in dogs were noted as early as day 2 and were generally sustained throughout the dosing periods. Clinical evidence of GI toxicity with avagacestat-related changes in the GI tract in dogs occurred at doses ! 3 mg/kg/day with associated reductions in circulating WBC HES-1 of 50%-60%. There was complete recovery of WBC HES-1 mRNA in chronically treated dogs after a 3-month recovery period that was consistent with the partial to complete recovery of Notch-related toxicities in the GI tract, lymphoid tissues, and ovaries. The absence of recovery for this downstream marker of Notch activity in female rats following a 3-month post dose recovery period, particularly at the lower doses, was unexpected considering that other Notch-related findings attributed to avagacestat administration in rats demonstrated dose-related partial to complete recovery and that there was full recovery from reduced WBC HES-1 mRNA levels in dogs treated with up to 6 mg/kg/day of avagacestat for 1 year. Since there was no evidence of opportunistic or secondary infections following chronic treatment in this study, suggesting that there was no compromise of leukocyte function in these animals, the biologic impact of decreased HES-1 mRNA levels in peripheral WBCs, other than as a biomarker for decreased Notch activity, is uncertain.
The ovarian changes in rats and dogs and associated alterations in estrous cyclicity were attributed to inhibition of Notch signaling pathways regulating oocyte differentiation/development because all Notch receptors (notches 1-4) are expressed in the mammalian ovary and notch receptors 2 and 3 are critical in the regulation of mammalian folliculogenesis (Hahn et al., 2005; Johnson et al., 2001; Keller Larkin et al., 1999; Trombly et al., 2009; Vanorny et al., 2014; Zhang et al., 2011) . Findings considered secondary to these effects on ovarian follicular development and associated disruption of the hypothalamic-pituitary-ovarian axis included increased pituitary gland weights with hypertrophy, hyperplasia, and vacuolation of pituitary gonadotrophs. Higher levels of gonadotropins are produced by the pituitary gland in response to decreases in serum estrogen and the absence of negative feedback from reduced serum levels of inhibin (De Jong, 1988; Rivier et al., 1986) and would be expected with follicular degeneration and ovarian atrophy. Ovarian proliferative changes (hypertrophy and hyperplasia of granulosa and thecal cells and benign granulosa-thecal cell tumors) were attributed to chronic trophic stimulation of granulosa and thecal cells by high levels of FSH and LH (observed in the 3-month oral toxicity study; see "Dose selection" section), rather than a direct effect of avagacestat. Persistent elevations in FSH and LH with associated induction of granulosa cell hyperplasia and tumors is a well-described epigenetic mechanism of granulosa-thecal cell tumorigenesis in rodents (Capen, 2004; Davis and Maronpot, 1996; Long et al., 2001; Matzuk et al., 1992) , and a similar epigenetic mechanism likely occurred in avagacestat-treated dogs. The epigenetic nature of these ovarian hyperplastic and tumorigenic responses is further supported by the fact that avagacestat was neither mutagenic nor clastogenic in the standard battery of genotoxicity studies (data not shown).
Treatment with avagacestat caused increased body weight and food consumption and associated hepatocellular lipid vacuolation in female rats at doses that also resulted in ovarian atrophy. As similar increases in body weight and food consumption (with reversal by estradiol supplementation) have been previously reported in ovariectomized rats (Asarian and Geary, 2002; Jiang et al., 2008) , these avagacestat-related increases in body weight and food intake in female rats were likely a consequence of reduced estrogen levels secondary to avagacestat-related atrophy of the ovaries. Although similar increases in body weight and food consumption were not observed in avagacestattreated female dogs, the more pronounced GI toxicity of avagacestat in this species as well as the prolonged anestrus period unique to the canine reproductive cycle (Concannon, 2009) were likely complicating factors. Considering the well-documented critical role of Notch signaling for regulation of T-versus B-cell development in higher vertebrates (Amsen et al., 2004; Baldi et al., 2004; Hollowood and Goodlad, 1998; Joshi et al., 2009; Palaga et al., 2003; Pui et al., 1999; Radtke et al., 1999; Wilson et al., 2001; Yun and Bevan, 2003) , the spectrum of avagacestat-related lymphoid changes identified in these studies, including decreases in circulating T and/or B cells and lymphoid depletion in lymph nodes and the spleen, were considered to be mechanism based. This conclusion was further supported by the B-cell depletion that has been demonstrated in RBP-J (a ubiquitous signal mediator of the Notch pathway) conditional knockout mice (Tanigaki et al., 2002) and in rats treated with other c-secretase inhibitors (Milano et al., 2004; Wong et al., 2004) . In RBP-J knockout mice, the depletion of B cells in the marginal zone of the spleen was attributed primarily to the lack of generation of these cells rather than a defect in their maintenance in lymphoid tissues (Saito et al., 2003) . Although Notch signaling has also been shown to have a key role in the innate immune and inflammatory responses in health and disease (Shang et al., 2016) , there were no signs of opportunistic or secondary infections in rats or dogs chronically treated with avagacestat, suggesting that these lymphoid changes were of limited clinical significance.
As Notch signaling regulates cell differentiation and proliferation contributing to the maintenance of intestinal epithelia (Barten et al., 2006; Radtke and Raj, 2003) and is critical for intestinal epithelial regeneration (Okamoto et al., 2009) , avagacestatrelated GI toxicity was also considered to be mechanism based. Epithelial cells in intestinal glands produce differentiated progeny that can develop along 2 distinct lineages, either an exocrine/secretory cell (goblet, enteroendocrine, or Paneth) or an absorptive cell (enterocyte) (Radtke and Clevers, 2005; Schonhoff et al., 2004) . Activation through Notch signaling promotes proliferation of intestinal progenitor cells and directs cell fate toward enterocytes (Fre et al., 2005; Stanger et al., 2005; van Es et al., 2005) , whereas the absence of Notch signaling (particularly for HES-1) directs cells toward the secretory phenotypes, especially goblet cells. Accordingly, goblet cell metaplasia has previously been described in HES-1 knockout mice and in rats and mice treated with other c-secretase inhibitors (Jensen et al., 2000; Milano et al., 2004; Searfoss et al., 2003) .
Avagacestat produced generally dose-related GI toxicity in subchronically (Albright et al., 2013) and chronically treated rats and dogs, with the most pronounced effects in dogs. GI toxicity identified in dogs at ! 3 mg/kg/day included goblet cell metaplasia (generally in the duodenum) accompanied by a spectrum of changes in multiple segments of the small and/or large intestines including dilatation with epithelial degeneration, necrosis, and regeneration in the intestinal glands and associated villous/mucosal atrophy, inflammation, and hemorrhage that likely reflected alterations in intestinal epithelial cell turnover and/or disruption of the enteric mucosal barrier. In contrast, although significantly higher plasma levels of avagacestat were observed in female rats compared with dogs in the chronic studies, there were no avagacestat-related GI changes in female rats after 6 months of treatment at up to 8 mg/kg/day. Differences in avagacestat-related GI effects between rats and dogs could be due to differences in species sensitivity to Notchmediated effects by avagacestat, as higher EC 50 values of plasma avagacestat for HES-1 reduction in rats (40 000 ngÁh/ml) compared with dogs (7000 ngÁh/ml) have been reported (Albright et al., 2013) . In addition, an adaptive response to avagacestat over time and/or an age-related decrease in the susceptibility of the small intestine to inhibition of Notch signaling in rats is suggested by a time-dependent reduction in goblet cell metaplasia. That is, despite a low incidence of minimal goblet cell metaplasia in the duodenum (Albright et al., 2013) at avagacestat doses of 30 and 100 mg/kg/day for 1 month (AUC exposure multiples of 12.2Â-15.8Â at the human clinical dose of 50 mg), goblet cell metaplasia was not observed in the 6-month study at exposure multiples of up to 12Â the human AUC. In a randomized, double-blind, placebo-controlled phase 2 clinical trial in mild to moderate AD (Coric et al., 2015) , GI adverse events (AEs) including diarrhea, nausea, and vomiting were a common cause of patient discontinuation. Avagacestat was well-tolerated at the 25 or 50 mg/day doses where there were no mean decreases in CSF Ab, but discontinuation rates were higher at doses where significant decreases in CSF Ab levels were observed (100 or 125 mg/day). Similarly, in a randomized, double-blind, placebo-controlled phase 2 clinical trial in prodromal AD patients (Coric et al., 2012) , although avagacestat was well tolerated at 50 mg (with high discontinuation rates at 125 mg primarily due to GI AE) it generated only modest reductions in Ab40 and Ab42 at the 50 mg dose. As in humans, GI toxicity in dogs was dose limiting; however, significant Ab reductions (22%-34%) were observed in dogs at doses that did not cause GI toxicity ( 1 mg/kg/day; 1.1Â human exposure).
In some early decedent dogs at ! 3 mg/kg/day with pronounced avagacestat-related GI injury, there was a spectrum of findings including ascites and microscopic changes in the liver (reactive Kupffer cells, inflammatory cell infiltrates, and occasional foci of hepatocellular necrosis with correlative increases in serum transaminases), pancreas (edema, inflammation, acinar cell degeneration, and necrosis of adipose tissue), gallbladder (edema and inflammation), and the testes (seminiferous tubular degeneration). Although avagacestat-related inhibition of Notch signaling cannot be completely discounted as having a contributory role in the changes in the pancreas and testes since Notch signaling has an established role in the development and regeneration of pancreatic acinar cells (Siveke et al., 2008; Su et al., 2006) , and in testicular Leydig cell function and proliferation and maturation of spermatogenic epithelial cells (Dirami et al., 2001; Hayashi et al., 2001; Sahin et al., 2005) , the absence of these findings in other dogs at the same dose levels and similar systemic exposures to avagacestat without clinical toxicity suggested that they were secondary to avagacestatrelated GI toxicity and extensive mucosal injury in the proximal small intestine and/or the poor physical condition of these early decedents rather than a direct effect of avagacestat.
In 1-and 3-month studies in female rats, avagacestatrelated effects on bone included hypertrophy of the hypertrophic zone of the epiphyseal growth plate cartilage of the femur, tibia, and sternum and increases in metaphyseal trabecular bone in the femur and tibia (data not shown). A similar change of increased trabecular bone (hyperostosis) in the sternum and femur at ! 2 mg/kg/day as well as a minimal to slight hypertrophy/hyperplasia of epiphyseal cartilage deep to the articular surface cartilage in the femoral head at ! 6 mg/kg/day were observed in females in the 6-month study indicating that the avagacestat-related bone alterations were dose and time dependent. Since Notch signaling has a key role in development and postnatal homeostasis of skeletal bone by regulating differentiation of bone mesenchymal cells and cells committed to osteoblastic or chondrocytic lineage (Engin et al., 2008; Weber and Calvi, 2010; Zanotti and Canalis, 2011) , the bone changes in female rats following treatment with avagacestat were also considered to be mechanism based. The hypertrophy/hyperplasia of the epiphyseal cartilage suggested impaired endochondral ossification, as the epiphyseal cartilage zones of proliferation and maturation were unremarkable. Because endothelial Notch activity promotes angiogenesis and osteogenesis in bone (Ramasamy et al., 2014) , it is plausible that impaired capillary invasion of the growth plate cartilage due to inhibition of Notch signaling resulted in altered or delayed endochondral ossification. The physes of long bones in the adult rat are not completely resorbed (Leininger and Riley, 1990) ; thus, potential sensitivity to this effect in rats would be expected throughout the 6-month dosing period. The increased thickness of intramedullary trabecular bone that was most prominent at the end of the 3-month recovery period likely reflected endochondral ossification of the thickened hypertrophic/hyperplastic zones of the epiphyseal growth plate cartilage. There was no evidence of the age-related osteoporosis that has been identified in mice lacking presenilin 1 and 2 (2 of the 4 proteins in the c-secretase complex) and resulting from increased osteoblast-dependent osteoclastic activity (Engin et al., 2008) . The absence of avagacestat-related bone changes in dogs likely reflected the absence of significant endochondral ossification, as animals in the 1-year toxicity study were between 9 and 13 months of age at the initiation of avagacestat treatment, and growth plates close between 6 and 12 months of age in beagle dogs (Yamasaki, 1995) .
Avagacestat induced dose-dependent renal changes in female rats characterized by proteinuria and microscopic glomerular injury with an increased incidence of CPN after chronic dosing. Importantly, this avagacestat-related effect on the kidney appears to be rat specific as no proteinuria or other indicators of glomerular injury were observed in dogs or in humans in clinical trials (Coric et al., 2012 (Coric et al., , 2015 . A mechanism for the adrenocortical hypertrophy with associated adrenal gland weight increases in avagacestat-treated female rats at ! 4 mg/kg/day was not established.
In conclusion, avagacestat demonstrated good oral tolerability in rats for 6 months at doses up 30 mg/kg/day (1.6Â human exposure) in males or 8 mg/kg/day (12Â) in females and in dogs for 1 year at doses up to 1 mg/kg/day (1.1Â). With chronic administration, there was a spectrum of pharmacologically mediated changes attributed to inhibition of Notch signaling. Specific mechanism-based findings included decreases in peripheral lymphocytes (T and/or B cells) and morphologic changes in the GI tract, lymphoid tissues, ovaries, and bones (rats only). Pharmacologically mediated changes in brain and CSF levels of Ab40 and Ab42 in the dog and expression of WBC mRNA levels of Notch-regulated genes confirmed target engagement at all doses.
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